2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

What happened: Innovent Biologics (HKEX: 01801) presented Phase 2 data at the 2026 ESMO Congress for IBI354, a HER2 ADC, combined with pertuzumab as first-line treatment for HER2-positive advanced breast cancer. Key numbers: 20 patients enrolled at 9mg/kg Q3W; median follow-up 9.6 months; cORR 95% and DCR 100%; 4 patients (20%) had Grade ≥3 TRAEs; 1 patient (5%) Why it matters: Innovent states two pivotal Phase 3 studies, HeriCare-Ovarian01 and HeriCare-Breast01, have been initiated, and says the data support its ADC platform for next-generation bispecific and dual-payload ADCs. Market: +2.1% today ($83.35), +5.8% YTD, 1.3x vol — as of 07:45 UTC

Innovent Biologics (HKEX: 01801) presented Phase 2 data at the 2026 ESMO Congress for IBI354, a HER2 ADC, combined with pertuzumab as first-line treatment for HER2-positive advanced breast cancer.

Innovent states two pivotal Phase 3 studies, HeriCare-Ovarian01 and HeriCare-Breast01, have been initiated, and says the data support its ADC platform for next-generation bispecific and dual-payload ADCs. Market: +2.1% today ($83.35), +5.8% YTD, 1.3x vol — as of 07:45 UTC